AI Article Synopsis
- The study investigates the safety and effectiveness of using an intravitreal dexamethasone implant during cataract surgery for patients with macular edema due to diabetic retinopathy or retinal vein occlusion.
- A total of 24 eyes were evaluated, with significant improvements in visual acuity and a decrease in central macular thickness noted over a median follow-up of 13 months, although some patients experienced recurrence of macular edema.
- The results suggest that this combined surgical approach is generally safe, with no major complications noted, but further research is needed to confirm its long-term benefits.
Article Abstract
Purpose: To study the safety and efficacy of intravitreal dexamethasone implant in patients with cataract and macular edema undergoing phacoemulsification and intraocular lens (IOL) implantation.
Methods: Twenty-four eyes with macular edema secondary to diabetic retinopathy (diabetic macular edema [DME]) and retinal vein occlusion (RVO) were retrospectively reviewed. These eyes underwent phacoemulsification with IOL implantation and intravitreal dexamethasone implant 0.7 mg at the same setting between September 2012 and September 2013. Demographic data, best-corrected visual acuity (BCVA), central macular thickness (CMT), intraocular pressure (IOP), surgical time, and complications were recorded.
Results: Twelve eyes had DME and 12 eyes had RVO (10 central RVO and 2 branch RVO). Median baseline logMAR BCVA was 1.0 (Snellen 20/200) and mean baseline CMT was 530.2 ± 218.9 µm. Median follow-up duration was 13 months. At last follow-up, median visual acuity improved significantly to 0.523 (Snellen 20/66) (p = 0.003) and CMT decreased to 300.7 ± 78.1 µm (p = 0.000). Median surgical time was 23 minutes. There were no intraoperative complications. In 12 eyes, macular edema recurred, requiring further treatment, and median time to recurrences was 21 weeks. One eye had raised IOP after second dexamethasone implant for recurrent macular edema. No major complication such as vitreous hemorrhage, retinal detachment, or endophthalmitis occurred.
Conclusions: Combined cataract surgery with intravitreal dexamethasone implant seems to be safe and effective in treating patients with cataract and macular edema in this small case series. A larger prospective study with longer follow-up is necessary to demonstrate the long-term benefit of this combined procedure.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.5301/ejo.5000523 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Surgical interventions for simple phakic fovea-splitting rhegmatogenous retinal detachment: a comparative study of scleral buckling and pars plana vitrectomy.
Front Med (Lausanne)
January 2025
National Clinical Research Center for Ocular Diseases, Eye Hospital, Wenzhou Medical University, Wenzhou, China.
Aims: To compare the efficiency of scleral buckling (SB) and pars plana vitrectomy (PPV) with or without SB in patients with primary simple phakic fovea-splitting rhegmatogenous retinal detachment (RRD).
Methods: A retrospective case-control study included 101 patients aged <55 years diagnosed with phakic fovea-splitting RRD. The primary outcome was functional success, defined as achieving a postoperative logarithm of the minimum angle of resolution best-corrected visual acuity of 0.
Correlating the Optical Coherence Tomography Patterns and Biomarkers of Diabetic Macular Edema with Hemoglobin Level in Diabetic Kidney Disease.
Clin Ophthalmol
January 2025
Department of Ophthalmology, Kasturba Medical College Manipal, Manipal Academy of Higher Education, Manipal, Udupi, Karnataka, India.
Purpose: To correlate the optical coherence tomography (OCT) based morphological patterns of diabetic macular edema (DME) and prognostic biomarkers with severity of anaemia in patients with diabetic kidney disease (DKD).
Patients And Methods: Single centre, observational cross sectional study of 42 eyes of 42 patients with DME and DKD. Eyes were divided into 2 groups: Group A (Haemoglobin level above 10 g% and group B with haemoglobin less than 10 g%).
Association Between HbA1c Levels and the Severity of Diabetic Retinopathy.
Cureus
December 2024
Department of Ophthalmology, College of Medicine, Qassim University, Kingdom of Saudi Arabia, Buraidah, SAU.
Background: Diabetic retinopathy (DR) is a significant microvascular complication of diabetes mellitus (DM), contributing to visual impairment and blindness worldwide. Understanding the factors associated with the severity of DR is crucial for effective prevention and management. This study aimed to explore the association between hemoglobin A1c (HbA1c) level and other parameters with different stages of DR.
View Article and Find Full Text PDFPharmacological blocking of microfibrillar-associated protein 4 reduces retinal neoangiogenesis and vascular leakage.
Mol Ther
January 2025
Department of Molecular Medicine, University of Southern Denmark; Odense, 5230, Denmark. Electronic address:
Neovascular age-related macular degeneration and diabetic macular edema are leading causes of vision-loss evoked by retinal neovascularization and vascular leakage. The glycoprotein microfibrillar-associated protein 4 (MFAP4) is an integrin αβ ligand present in the extracellular matrix. Single-cell transcriptomics reveal MFAP4 expression in cell-types in close proximity to vascular endothelial cells including choroidal vascular mural cells and retinal astrocytes and Müller cells.
View Article and Find Full Text PDFThrombolytic efficacy and safety of recombinant scu-PA in a rabbit retinal vein occlusion model.
Eur J Pharmacol
January 2025
Tianjin Key Laboratory of Retinal Functions and Diseases, Tianjin Branch of National Clinical Research Center for Ocular Disease, Eye Institute and School of Optometry, Tianjin Medical University Eye Hospital. Electronic address:
Retinal vein occlusion (RVO) has become the second most common retinal vascular disease after diabetic retinopathy. Existing therapeutic approaches, including intravitreal injection of antivascular endothelial growth factors (anti-VEGFs) and/or glucocorticoids and laser therapy, primarily address secondary macular edema and neovascularisation. However, these strategies do not address the underlying cause of the disease and may have harmful side effects.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!